Motif Neurotech Raises $18.75 Million in Series A Financing to Advance Implantable Device for Treatment-Resistant Depression

Motif Neurotech, a neurotechnology company developing minimally-invasive bioelectronics for mental health, announced today an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Capital, Dolby Family Ventures, re.Mind Capital, individual investor Max Hodak, and existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory.